Search results for "disorder"

showing 10 items of 6405 documents

Multi-Dimensional, Short-Timescale Quantification of Parkinson's Disease and Essential Tremor Motor Dysfunction

2020

Introduction: Parkinson's disease (PD) is a progressive movement disorder characterized by heterogenous motor dysfunction with fluctuations in severity. Objective, short-timescale characterization of this dysfunction is necessary as therapies become increasingly adaptive. Objectives: This study aims to characterize a novel, naturalistic, and goal-directed tablet-based task and complementary analysis protocol designed to characterize the motor features of PD. Methods: A total of 26 patients with PD and without deep brain stimulation (DBS), 20 control subjects, and eight patients with PD and with DBS completed the task. Eight metrics, each designed to capture an aspect of motor dysfunction in…

0301 basic medicinemedicine.medical_specialtyDeep brain stimulationParkinson's diseaseMovement disordersMotor dysfunctionmedicine.medical_treatmentbehavioral disciplines and activitieslcsh:RC346-429Correlation03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationmedicinelcsh:Neurology. Diseases of the nervous systemOriginal ResearchUPDRSsymptom assessmentEssential tremorbusiness.industryessential tremor (ET)medicine.diseaseControl subjectsdeep brain stimulationmachine learning030104 developmental biologyNeurologyMulti dimensionalNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgeryParkinson's Disease (PD)Frontiers in Neurology
researchProduct

Pain-induced alterations in the dynorphinergic system within the mesocorticolimbic pathway: Implication for alcohol addiction.

2020

Latest studies have revealed that pain negatively impacts on reward processing and motivation leading to negative affective states and stress. These states not only reduce quality of life of patients by increasing the appearance of psychiatric comorbidities, but also have an important impact on vulnerability to drug abuse, including alcohol. In fact, clinical, epidemiological but also preclinical studies have revealed that the presence of pain is closely related to alcohol use disorders (AUDs). All this evidence suggests that pain is a factor that increases the risk of suffering AUD, predicting heavy drinking behavior and relapse drinking in those patients with a previous history of AUD. Th…

0301 basic medicinemedicine.medical_specialtyDopamineAlcohol use disorderMesolimbic pathwayκ-opioid receptor03 medical and health sciencesCellular and Molecular NeuroscienceReward system0302 clinical medicineQuality of lifeRewardmental disordersmedicineHumansPsychiatrybusiness.industryDopaminergicChronic painmedicine.diseaseSubstance abuseAlcoholism030104 developmental biologyQuality of LifeChronic Painbusiness030217 neurology & neurosurgeryJournal of neuroscience researchREFERENCES
researchProduct

Neurotransmitters and Behavioral Alterations Induced by Nickel Exposure.

2020

Background:: Nickel ions (Ni2+) are a heavy metal with wide industrial uses. Environmental and occupational exposures to Ni are potential risk factors for brain dysfunction and behavioral and neurological symptoms in humans. Methods: We reviewed the current evidence about neurochemical and behavioral alterations associated with Ni exposure in laboratory animals and humans. Results: Ni2+ exposure can alter (both inhibition and stimulation) dopamine release and inhibit glutamate NMDA receptors. Few reports claim an effect of Ni2+ at the level of GBA and serotonin neurotransmission. At behavioral levels, exposure to Ni2+ in rodents alters motor activity, learning and memory as well as anxiety…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationStimulationEnvironmental Illness03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNeurochemicalDopamineNickelInternal medicineImmunology and AllergyMedicineAnimalsHumanseducationNeurotransmittereducation.field_of_studyBehaviorNeurotransmitter Agentsbusiness.industryMental DisordersGlutamate receptorEnvironmental Exposure030104 developmental biologyEndocrinologychemistryNMDA receptorSerotoninbusiness030217 neurology & neurosurgerymedicine.drugEndocrine, metabolicimmune disorders drug targets
researchProduct

Vitamin D across growth hormone (GH) disorders: From GH deficiency to GH excess

2017

The interplay between vitamin D and the growth hormone (GH)/insulin-like growth factor (IGF)-I system is very complex and to date it is not fully understood. GH directly regulates renal 1 alpha-hydroxylase activity, although the action of GH in modulating vitamin D metabolism may also be IGF-I mediated. On the other hand, vitamin D increases circulating IGF-I and the vitamin D deficiency should be normalized before measurement of IGF-I concentrations to obtain reliable and unbiased IGF-I values. Indeed, linear growth after treatment of nutritional vitamin D deficiency seems to be mediated through activation of the GH/IGF-I axis and it suggests an important role of vitamin D as a link betwee…

0301 basic medicinemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismGrowth hormonevitamin D deficiencySettore MED/13 - EndocrinologiaGrowth hormone deficiency03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineAcromegalyVitamin D and neurologyHumansMedicineInsulin-Like Growth Factor IVitamin DGrowth Disordersgrowth hormone vitamin DHuman Growth Hormonebusiness.industryGrowth factormedicine.diseaseGrowth hormone treatment030104 developmental biologyEndocrinologyAcromegalybusinessGH DeficiencyGrowth Hormone & IGF Research
researchProduct

Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study

2020

Abstract Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment. Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychological evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hyper…

0301 basic medicinemedicine.medical_specialtyEpidemiologyNeuropsychological Testsbehavioral disciplines and activitiesWhite matter lesions03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyHumansMedicineDementiaCognitive DysfunctionLongitudinal StudiesRisk factorCognitive declineOriginal CommunicationFramingham Risk Scorebusiness.industryMild cognitive impairmentParkinson DiseaseEpidemiology Hypertension Mild cognitive impairment Parkinson’s disease Risk factors White matter lesions Humans Longitudinal Studies Neuropsychological Tests Risk Factors Cognitive Dysfunction Parkinson Disease White Mattermedicine.diseaseWhite MatterHyperintensitynervous system diseases030104 developmental biologyBlood pressureRisk factorsNeurologyHypertensionCohortParkinson’s diseaseNeurology (clinical)business030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Altered synaptic phospholipid signaling in PRG-1 deficient mice induces exploratory behavior and motor hyperactivity resembling psychiatric disorders.

2017

Abstract Plasticity related gene 1 (PRG-1) is a neuron specific membrane protein located at the postsynaptic density of glutamatergic synapses. PRG-1 modulates signaling pathways of phosphorylated lipid substrates such as lysophosphatidic acid (LPA). Deletion of PRG-1 increases presynaptic glutamate release probability leading to neuronal over-excitation. However, due to its cortical expression, PRG-1 deficiency leading to increased glutamatergic transmission is supposed to also affect motor pathways. We therefore analyzed the effects of PRG-1 function on exploratory and motor behavior using homozygous PRG-1 knockout (PRG-1−/−) mice and PRG-1/LPA2–receptor double knockout (PRG-1−/−/LPA2−/−)…

0301 basic medicinemedicine.medical_specialtyGlutamic AcidNerve Tissue ProteinsBiologyHyperkinesisHippocampusOpen field03 medical and health sciencesBehavioral NeuroscienceGlutamatergicchemistry.chemical_compoundMice0302 clinical medicineLysophosphatidic acidmedicineAnimalsReceptors Lysophosphatidic AcidPsychiatryMice KnockoutNeuronsMental DisordersGlutamate receptorSomatosensory CortexMice Inbred C57BL030104 developmental biologymedicine.anatomical_structurechemistrySynapsesExploratory BehaviorGABAergicCalmodulin-Binding ProteinsFemaleNeuronSignal transductionLysophospholipidsPostsynaptic density030217 neurology & neurosurgerySignal TransductionBehavioural brain research
researchProduct

International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome

2018

Abstract Aim Mucopolysaccharidosis type I is a lysosomal storage disorder that can result in significant disease burden, disability and premature death, if left untreated. The aim of this review was to elaborate on the diagnosis of mucopolysaccharidosis type I and the pros and cons of newborn screening. Methods An international working group was established to discuss ways to improve the early diagnosis of mucopolysaccharidosis type I. It consisted of 13 experts in paediatrics, rare diseases and inherited metabolic diseases from Europe and the Middle East. Results It is becoming increasingly clearer that the delay between symptom onset and clinical diagnosis is considerable for mucopolysacc…

0301 basic medicinemedicine.medical_specialtyHaematopoietic stem cell transplantLysosomal storage disorderMucopolysaccharidosis ILysosomal storage disordersReview ArticleDisease03 medical and health sciencesMucopolysaccharidosis type INeonatal Screening0302 clinical medicinemedicineHumansLaronidasePediatrics Perinatology and Child HealthIntensive care medicineReview ArticlesDisease burdenNewborn screeningbusiness.industryMucopolysaccharidosis type IInfant NewbornGeneral MedicineEnzyme replacement therapyInternational working group030104 developmental biologyEnzyme replacement therapyClinical diagnosisPediatrics Perinatology and Child Healthbusiness030217 neurology & neurosurgeryActa Paediatrica
researchProduct

Lubricin in synovial fluid of mild and severe temporomandibular joint internal derangements

2015

Background To understand the molecular basis of temporomandibular joint (TMJ) pathologies, we aimed to investigate the lubricin levels in the TMJ synovial fluid (SF) of patients with mild to severe internal derangements (IDs). Material and Methods A total, 34 joints were the study group. Only patients, with a Wilkes stage of III, IV and V were included, in this sample. Control group consisted of SF from eight joints, from patients undergoing to orthognatic surgery. Concentrations of lubricin in the SF from both samples were measured using ELISA system. Results The mean lubricin concentration was 7.029 ± 0.21 µg/mL in stage III patients; 5.64 ± 0.10 µg/mL in stage IV patients, and 4.78 ± 0.1…

0301 basic medicinemedicine.medical_specialtyJoint cavitylubricin; synovial fluid; TMJGastroenterology03 medical and health sciences0302 clinical medicinesynovial fluidDisease severityInternal medicinemedicineHumansSynovial fluidStage (cooking)General DentistryGlycoproteinsVas scoreTemporomandibular Jointbusiness.industryResearch030206 dentistryTemporomandibular Joint Disorders:CIENCIAS MÉDICAS [UNESCO]Control subjectsTMJTemporomandibular jointSurgeryOrofacial Pain-TMJDCross-Sectional Studies030104 developmental biologymedicine.anatomical_structureOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgerylubricinStage ivbusiness
researchProduct

Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders

2021

Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classification 1970) divided the primary hyperviscosity syndromes in polycythaemic, sclerocytemic and sieric. Recent and personal laboratory observations have highlighted an unexpected behaviour of the erythrocyte deformability observed in some haematological disorders such as polycythemia vera, multiple myeloma and monoclonal gammopathy of undetermined significance. The interest of this observation depends on the fact that up to now, according to the Wells cla…

0301 basic medicinemedicine.medical_specialtyLaboratory findingHyperviscosityMonoclonal gammopathy of undetermined significance030204 cardiovascular system & hematologyBiochemistryHyperviscosity syndromes03 medical and health sciences0302 clinical medicinePolycythemia veraMultiple myelomaErythrocyte DeformabilityHyperviscosity syndromemedicineAnimalsHumansIntensive care medicinePolycythemia VeraMultiple myelomabusiness.industryModels CardiovascularCell Biologymedicine.diseaseBlood Viscosity030104 developmental biologyAbnormalityCardiology and Cardiovascular MedicinebusinessMonoclonal gammopathy of undetermined significanceHaematological disorders
researchProduct

Effect of high-frequency subthalamic neurostimulation on gait and freezing of gait in Parkinson's disease: a systematic review and meta-analysis.

2016

The aim of this meta-analysis was to summarize the short- and long-term effects of bilateral deep brain stimulation of the subthalamic nucleus (STN-DBS) on gait and freezing of gait (FOG) in Parkinson's disease and to detect predictors of post-stimulation outcome. A comprehensive review of the literature was conducted up to October 2015 using Medline Ovid databases for studies analyzing the effect of bilateral STN-DBS on FOG and/or gait. Sixteen studies with available data for the gait item (no. 29) of the Unified Parkinson's Disease Rating Scale (UPDRS) and six studies with the FOG item (no. 14) were included. Data were summarized for the following follow-up periods: 6-15, 24-48 and48 mont…

0301 basic medicinemedicine.medical_specialtyLevodopaDeep brain stimulationParkinson's diseasemedicine.medical_treatmentDeep Brain Stimulation03 medical and health sciences0302 clinical medicineGait (human)Physical medicine and rehabilitationRating scaleSubthalamic NucleusmedicineHumansNeurostimulationGaitGait Disorders Neurologicbusiness.industryParkinson Diseasemedicine.diseasenervous system diseasesSubthalamic nucleus030104 developmental biologyTreatment OutcomeNeurologyMeta-analysisPhysical therapyNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugEuropean journal of neurology
researchProduct